Heraldo Mendes Garmes

Prof. Dr. Heraldo Mendes Garmes


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Gynecological Endocrinology
Verified
Journal Article
Closed access
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes
MTMarcos A. Tambascia
Marcos A. Tambascia
DZDenise E. Zantut-Wittmann
Denise E. Zantut-Wittmann
The hyperandrogenism found in polycystic ovary syndrome (PCOS) can be a consequence of hyperinsulinemia as a result of peripheral insulin resistance. Metformin and insulin sensitizers have become a potential therapeutic tool for treating these patients; however, there are few studies with pioglitazone in PCOS. Elevated luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratios and LH hyper-responsivity to stimulation with gonadotropin-releasing hormone (GnRH) are common findings in PCOS. The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown. In the present study, we evaluated the effect of pioglitazone (30 mg/day for 2 months) on insulin response to an oral glucose tolerance test (OGTT), serum levels of androgens and sex hormone-binding globulin (SHBG), and pituitary gonadotropin response to GnRH stimulation in 15 obese PCOS women. We found a significant decrease in insulin response to the OGTT and also in total and free testosterone levels, an increase in SHBG and a reduction in the LH response to GnRH stimulation after pioglitazone treatment. In conclusion, this short-term treatment with pioglitazone decreased hyperinsulinemia and hyperandrogenemia in obese PCOS patients, and there was a significant reduction in LH response to GnRH stimulation. Further research should be carried out to establish the risks and benefits of pioglitazone, which would assist in the physiopathologic comprehension of PCOS.

1 January 2017 in Surgical Neurology International
Verified
Journal Article
Open access
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes
JCJosébarreto Campello Carvalheira
Josébarreto Campello Carvalheira
FRFabiano Reis
Fabiano Reis
LQLucianode Souza Queiroz
Lucianode Souza Queiroz
MFMateusDal Fabbro
MateusDal Fabbro
ASAllande Oliviera Santos
Allande Oliviera Santos
The present case of an aggressive pituitary carcinoma rising from a typical adenoma illustrates the importance of developing new prognostic biomarkers in these cases. In addition to demonstrating a serious side effect with the use of temozolomide, our case report suggests that the combined use of Ga-68 DOTATATE and F-18 FDG PET-CT scan may scale somatostatin receptors vs. tumor aggressiveness, therefore, helping to better choose the therapy for aggressive pituitary tumors.

31 January 2012 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes
OGOswaldo Rocha Grassiotto
Oswaldo Rocha Grassiotto
YFYvens Barbosa Fernandes
Yvens Barbosa Fernandes
LQLuciano de Souza Queiroz
Luciano de Souza Queiroz
JVJosé Vassalo
José Vassalo
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto

1 January 2019 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes
ACAlejandro Rosell Castillo
Alejandro Rosell Castillo
GH is one of the insulin counterregulatory hormones which acts in the opposite way to insulin, increasing the glucose production by the liver and kidneys and decreasing glucose uptake from peripheral tissues, thus being a hyperglycemic hormone. When in excess, as in acromegaly, it induces glucose intolerance and diabetes. As expected, patients with GH deficiency (GHD) have hypoglycemia, especially in early childhood, but as GH is also a lipolytic hormone, these patients are becoming obese with higher percentages of body fat. Although obesity in general is directly related to insulin resistance, in patients with GH secretion disorders this relationship may be altered. In acromegaly there is a decrease in fat mass with worsening insulin sensitivity and mice with isolated GHD are characterized by greater insulin sensitivity despite excess fat mass. In humans with GHD, body composition shows increased body fat and decreased free fat mass, but the results regarding insulin sensitivity are still controversial in these patients. These discrepant results regarding insulin sensitivity in patients with GHD suggest the existence of other variables influencing these results. In the present review, we will try to follow the path of the different researches conducted on this subject, both in animal and human models, with the goal of understanding the current knowledge of insulin sensitivity across the spectrum of GHD. Arch Endocrinol Metab. 2019;63(6):582-91.

25 January 2024 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes

25 February 2021 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HGHeraldo Mendes Garmes
Heraldo Mendes Garmes
CBCésar Luiz Boguszewski
César Luiz Boguszewski
PMPaulo Augusto Carvalho Miranda
Paulo Augusto Carvalho Miranda
MMManoel Ricardo Alves Martins
Manoel Ricardo Alves Martins
SSSilvia Regina Correa da Silva
Silvia Regina Correa da Silva
MBMarcello Delano Bronstein
Marcello Delano Bronstein
Hypopituitarism is a disorder characterized by insufficient secretion of one or more pituitary hormones. New etiologies of hypopituitarism have been recently described, including head trauma, cerebral hemorrhage, and drug-induced hypophysitis. The investigation of patients with these new disorders, in addition to advances in diagnosis and treatment of hypopituitarism, has increased the prevalence of this condition. Pituitary hormone deficiencies can induce significant clinical changes with consequent increased morbidity and mortality rates, while hormone replacement based on current guidelines protects these patients. In this review, we will first discuss the different etiologies of hypopituitarism and then address one by one the clinical aspects, diagnostic evaluation, and therapeutic options for deficiencies of TSH, ACTH, gonadotropin, and GH. Finally, we will detail the hormonal interactions that occur during replacement of pituitary hormones.